US Patent Issued to University of Washington, ABACUS BIOSCIENCE on Dec. 16 for "Therapeutic vaccine for hepatitis b virus (HBV) using the HBV core antigen" (Washington Inventors)

ALEXANDRIA, Va., Dec. 16 -- United States Patent no. 12,496,339, issued on Dec. 16, was assigned to University of Washington (Seattle) and ABACUS BIOSCIENCE INC. (Sammamish, Wash.).

"Therapeutic vaccine for hepatitis b virus (HBV) using the HBV core antigen" was invented by Edward A. Clark (Seattle), Deborah L. Fuller (Seattle), Che-Leung Law (Seattle) and Amanda Mak (Seattle).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are compositions of CD1280 binding proteins and a Hepatitis B virus core antigen (HBcAg) and/or a Hepatitis B virus E antigen (HBeAg), or antigenic fragments or mutants thereof, attached to the CD180 binding protein, and methods for using the compositions to treat or limit t...